This page shows what was measured, who it was measured in, and what that does not settle.
What Resveratrol does in the body
Sold for longevity and heart health, but not approved for either.
The original story was that resveratrol switches on an enzyme called SIRT1 that mimics the effects of eating less, and that this explains longer life in yeast, worms and mice. That story has two holes. In 2010 a pharmaceutical group showed the SIRT1 activation was an artefact of the fluorescent tag used in the assay: with a normal substrate, resveratrol does not activate the enzyme. And in humans, oral resveratrol is absorbed and then almost entirely conjugated within minutes, so the blood carries the deactivated form.
What happened in people
Independent human studies have repeatedly found no clear health benefit.
✓ Reviewed first-read answer
Where this came from
A person wrote this and a reviewer approved it against this exact record. It carries no effect size.
A reviewer approved this against this record. The reviewed-claim record carrying the exact population and effect size does not exist yet.
No source is stored against this line.
The limit that matters most
The proposed biological target was not directly engaged, and influential laboratory work was later found unreliable.
Where it acts
Intestinal epithelium and liver, where it is conjugated before reaching tissue
Kind of result
The kind of result is not recorded
Supervision
Not usually supervised: sold as a supplement or food ingredient where recorded. That is a legal category, not a safety judgement.
What the registries record it as
The supplement label database classes it as non-nutrient/non-botanical, under the name Resveratrol.
7 registered substances share the start of this name, which is why a search for it can return more than one thing.
FDA substance registry · AUA0K06FSB · read 2026-08-29
Where each sentence above came from
The recorded explanation is written in label language rather than for a beginner. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
The limit a reviewer approved as the one that matters most here.
The four opening statements run to 109 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Randomisation
Randomisation means chance decides who gets which treatment.
A picture of it, and where the picture fails
It is like a coin toss deciding the groups.
Where that stops being true. A coin toss is fair once. Fairness here comes from doing it for everyone.
What people get wrong. It is thought to make groups identical. It makes them similar on average, including on things nobody measured.
Allocation of participants to arms by a chance process, so that unmeasured factors are balanced in expectation.
Confidence interval
A confidence interval is the range the true answer is likely to sit in.
A picture of it, and where the picture fails
It is like a weather forecast giving a range rather than one number.
Where that stops being true. A forecast range covers tomorrow. This one covers what the study could resolve.
What people get wrong. The middle number is read as the answer. A range crossing zero means no change is still possible.
An interval estimate that would contain the true parameter in a stated proportion of repeated studies.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Blood sugar
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved3 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Cholesterol
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved3 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Endurance
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Pain
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
…Waiting for a reviewer1 registered symptom measure.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
triglycerides levels at week 12; total cholesterol; ldl/hdl
Endurance
aerobic capacity
Pain
pain scores measured by vas at day 42
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
△ Only a number moved
3 registered test measure.
— Not recorded
Harms were not a registered measure for this goal.
… Waiting for a reviewer
Who was studied is listed further down the page.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Insulin sensitivity by hyperinsulinaemic euglycaemic clamp after four weeks
✗ The study did not show it
Who was studied
Poulsen 2013 (high-dose resveratrol in obese men)
How many people
24
Study design
Randomised, double-blind, placebo-controlled, parallel group
Compared against
A dummy treatment
Kind of result
A number that stands in for health
What was found
No significant difference; insulin sensitivity deteriorated insignificantly in both arms
Repeated elsewhere
Replicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No effect on any secondary endpoint either: blood pressure, resting energy expenditure, lipid oxidation, ectopic or visceral fat, inflammatory or metabolic biomarkers.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral capsule of trans-resveratrol, usually extracted from Polygonum cuspidatum
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
University of Connecticut Health Center. Scientific Journals Notified Following Research Misconduct Investigation, 11 January 2012 (https://today.uconn.edu/2… · a recorded source, not a stored snapshot
Insulin sensitivity by two-stage hyperinsulinaemic euglycaemic clamp with labelled tracer infusion, after 12 weeks
✗ The study did not show it
Who was studied
Yoshino 2012 (75 mg/day for 12 weeks, nonobese postmenopausal women)
How many people
45
Study design
Randomised, double-blind, placebo-controlled
Compared against
A dummy treatment
Kind of result
A number that stands in for health
What was found
No significant improvement in any measure of metabolic function
Repeated elsewhere
Replicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. Forty-five women randomised across three arms of 15 — placebo, resveratrol 75 mg/day, and calorie restriction — so the resveratrol comparison itself rests on 15 against 14 completers. Resveratrol did not affect AMPK, SIRT1, NAMPT or PPARGC1A in muscle or adipose tissue.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral capsule of trans-resveratrol, usually extracted from Polygonum cuspidatum
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
University of Connecticut Health Center. Scientific Journals Notified Following Research Misconduct Investigation, 11 January 2012 (https://today.uconn.edu/2… · a recorded source, not a stored snapshot
Training-induced change in cardiovascular health parameters over eight weeks
✗ The study did not show it
Who was studied
Gliemann 2013 (resveratrol with high-intensity training in aged men)
How many people
27
Study design
Randomised, double-blind, placebo-controlled
Compared against
A dummy treatment
Kind of result
A number that stands in for health
What was found
P < 0.05 in favour of placebo for maximal oxygen uptake, mean arterial pressure and blood lipids
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. This trial did not merely fail to show benefit — the resveratrol arm did worse than placebo on the training response, which is a harm signal in a healthy population.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral capsule of trans-resveratrol, usually extracted from Polygonum cuspidatum
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
University of Connecticut Health Center. Scientific Journals Notified Following Research Misconduct Investigation, 11 January 2012 (https://today.uconn.edu/2… · a recorded source, not a stored snapshot
P = 0.67 across quartiles; HR 0.80 (95% CI 0.54 to 1.17) lowest versus highest
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. Observational, so confounding cannot be excluded — but the exposure measure is biochemical rather than a dietary questionnaire, which is stronger than most nutritional epidemiology.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral capsule of trans-resveratrol, usually extracted from Polygonum cuspidatum
Interval reported. 95% CI 0
Written into the record, not signed off as a reviewed claim.
University of Connecticut Health Center. Scientific Journals Notified Following Research Misconduct Investigation, 11 January 2012 (https://today.uconn.edu/2… · a recorded source, not a stored snapshot
RNAWiki holds 4 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
□Living longer, or avoiding a major eventNo evidence recorded. Death, a heart attack, a stroke, a hospital stay.No registered study measures this.
■What a body can do day to dayEvidence recorded. Walking, dressing, breathing, recovering.3 registered measures of this kind.
■Measured performanceEvidence recorded. How much was lifted, how far was run, how fast.3 registered measures of this kind.
■Symptoms and quality of lifeEvidence recorded. Pain, tiredness, mood, sleep, as the person rated it.2 registered measures of this kind.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.17 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.2 registered measures inside human tissue.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Yeast, C. elegans (roundworm), Drosophila (fruit fly), Mouse, Rat, Dog. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it changes in the body◇Read from sources, not yet reviewed
The path through the body
From what a person takes to what changes. A solid line is a step measured in people. A dashed line is a step nobody has measured that way.
Start
Resveratrol
What a person takes: Oral capsule of trans-resveratrol, usually extracted from Polygonum cuspidatum.
The measurement behind this step
Sold as a dietary supplement with no premarket efficacy review. Almost all commercial resveratrol comes from Japanese knotweed root rather than grapes; emodin, a laxative anthraquinone from the same root, is the impurity to watch and is not always specified. trans-Resveratrol isomerises to the cis form on light exposure.
Getting in
Absorbed well, and then almost entirely deactivated
Resveratrol crosses the gut wall easily and is then tagged for disposal within minutes, so very little free compound reaches the bloodstream.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
Oral absorption is roughly 70%, but first-pass glucuronidation and sulfation in enterocytes and hepatocytes are so extensive that free trans-resveratrol in plasma is typically in the low nanomolar range while conjugates are in the micromolar range. Almost every cell experiment uses free resveratrol at 10 to 100 micromolar.
University of Connecticut Health Center. Scientific Journals Notified Following Research Misconduct Investigation, 11 January 2012 (https://today.uconn.edu/2… · a recorded source, not a stored snapshot
The conjugates circulate; whether they are active is unresolved
What actually travels around the body is the tagged version, and nobody has established that it does anything.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Resveratrol-3-O-glucuronide and resveratrol-3-O-sulfate are the dominant circulating species. A partial deconjugation hypothesis at target tissue exists and has not been demonstrated at the concentrations an oral dose produces.
University of Connecticut Health Center. Scientific Journals Notified Following Research Misconduct Investigation, 11 January 2012 (https://today.uconn.edu/2… · a recorded source, not a stored snapshot
The enzyme the whole story was built on is not activated by resveratrol when the test is run properly.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
Pacholec et al. showed the apparent SIRT1 activation required a fluorophore-conjugated peptide substrate and vanished with native substrates. Gliemann et al. separately measured SIRT1 protein in trained older men and found it unaffected by resveratrol supplementation.
University of Connecticut Health Center. Scientific Journals Notified Following Research Misconduct Investigation, 11 January 2012 (https://today.uconn.edu/2… · a recorded source, not a stored snapshot
Indirect routes remain plausible and unproven in humans
Other explanations exist — mild mitochondrial stress, effects on an energy-sensing enzyme — but none has been shown to happen in a person.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
Proposed indirect mechanisms include AMPK activation downstream of phosphodiesterase inhibition and mild mitochondrial complex I inhibition. Each is reported at concentrations well above measured human free plasma levels.
University of Connecticut Health Center. Scientific Journals Notified Following Research Misconduct Investigation, 11 January 2012 (https://today.uconn.edu/2… · a recorded source, not a stored snapshot
And in the best human trials, nothing happens — or worse
The trials that controlled everything properly found no benefit, and one found resveratrol cancelled out the benefits of exercise.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
Poulsen 2013 and Yoshino 2012 found no metabolic effect in obese men and in nonobese women respectively. Gliemann 2013 found a 45% smaller training-induced rise in maximal oxygen uptake in the resveratrol arm, and abolition of the exercise-induced lipid improvements.
University of Connecticut Health Center. Scientific Journals Notified Following Research Misconduct Investigation, 11 January 2012 (https://today.uconn.edu/2… · a recorded source, not a stored snapshot
No suggested links are held for this record, so nothing is hidden from this path.
What we know
The record describes 5 steps from taking it to an effect in a person.
How we know it
Each step names the study behind it in the technical detail beside it.
What this does not prove
A change inside the body is a reason to look. It is not a result in a person.
Why it matters
A reader can see exactly where the chain stops being measured in people.
What we still do not know
No reviewed claim binds any of these steps to a named population.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
quality of life
pain scores measured by vas at day 42
Measured
Things only a test, a scale or a device shows.
brachial artery flow mediated dilation
c reactive protein
glucose control
insulin sensitivity
triglycerides levels at week 12
systolic blood pressure at week 12
waist circumference at week 12
diastolic blood pressure at week 12
relative gene expression by real time pcr
mitochondrial function
and 11 more.
Meaningful
Things that change how a life goes, not only a number.
walking speed
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (16)
auditory verbal learning task
metabolic parameters
nf kb
vascular function
adverse events
aerobic capacity
liver fat content
cardiac function
beta cell function
alaninaminotransferase
high density lipoprotein levels at week 12
total antioxidant activity
vitamin e
area under the curve
overall gulf war illness disease severity
post ercp pancreatitis
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 9.2 ± 0.6 hours hours
Read from the label, which states: “The absorption of a dietary relevant 25-mg oral dose was at least 70%, with peak plasma levels of resveratrol and metabolites of 491 +/- 90 ng/ml (about 2 microM) and a plasma half-life of 9.2 +/- 0.6 h.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Adults taking it for longevity, cardiovascular or metabolic reasons, usually on the strength of animal and cell literature rather than human trials.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
Where the result stopped carrying
The metabolic hypothesis failed in both directions: no effect in obese insulin-resistant men, no effect in lean metabolically healthy women
The exercise-adjunct hypothesis failed in the opposite direction from expected, with resveratrol blunting training benefits
The mechanistic foundation failed when the assay artefact was identified in 2010
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment.
On this record: The trials that controlled everything properly found no benefit, and one found resveratrol cancelled out the benefits of exercise.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
The product may not be what it says
Contents of a sold product are not always what the label states.
On this record: This is sold as a supplement, so no agency checked what is in a given tub before it was sold.
Other reasons RNAWiki checked and found nothing for (8)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Varies by country
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral capsule of trans-resveratrol, usually extracted from Polygonum cuspidatum
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Not usually supervised: sold as a supplement or food ingredient where recorded. That is a legal category, not a safety judgement.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
The identity record classes it as a supplement ingredient; no medicines register records an approval.
No source is stored against this line.
What is in the pack
Sold as a dietary supplement with no premarket efficacy review. Almost all commercial resveratrol comes from Japanese knotweed root rather than grapes; emodin, a laxative anthraquinone from the same root, is the impurity to watch and is not always specified. trans-Resveratrol isomerises to the cis form on light exposure.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take◇Read from sources, not yet reviewed
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
·Worth asking a clinician aboutWritten into the record from the studies named on this page
High doses produce gastrointestinal effects including nausea and diarrhoea, some of which may be residual emodin rather than resveratrol. Resveratrol inhibits CYP3A4 and CYP2C9 and has antiplatelet activity, giving a plausible interaction with anticoagulants. The one signal from a controlled trial is the blunting of exercise training adaptations in older men.
Nobody counted how many people took this and were fine, so this cannot be turned into a rate.
University of Connecticut Health Center. Scientific Journals Notified Following Research Misconduct Investigation, 11 January 2012 (https://today.uconn.edu/2… · a recorded source, not a stored snapshot
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Resveratrol appears in spontaneous reports to regulators. Across the 2 most-reported reaction terms, 12 reaction mentions were counted. One report can name several reactions.
The recorded terms (2)
hepatitis — 6 reaction mentions
hyperbilirubinaemia — 6 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral capsule of trans-resveratrol, usually extracted from Polygonum cuspidatum
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Almost all commercial resveratrol comes from Japanese knotweed root rather than grapes; emodin, a laxative anthraquinone from the same root, is the impurity to watch and is not always specified. trans-Resveratrol isomerises to the cis form on light exposure.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on which forms are sold and how they compare.
No source is stored against this line.
What is recorded as being sold
1 product lists this as an active ingredient in the United States drug directory. 1 of them contain it and nothing else.
FDA National Drug Code directory · 84242-001 · read 2026-08-29
They are sold as powder.
FDA National Drug Code directory · 84242-001 · read 2026-08-29
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
Watching one thing carefully can tell you whether it moved. It cannot tell you what moved it.
This is sold without a prescription, so a person can sensibly watch one thing and see whether it moves.
Pick one goal. One goal only. Two at once cannot be told apart afterwards.
Pick one thing to watch. Registered studies measured things like: brachial artery flow mediated dilation; c reactive protein; glucose control.
Measure before you start. Take the same measurement several times first. One reading is not a starting point.
Know the swing. Write down how much it moves on its own across a normal week.
Change one thing. Change nothing else at the same time, including training and sleep.
Give it the study length. No finished study window is recorded, so no length is suggested here.
Track whether you took it. Missed days are the most common reason a home test shows nothing.
Read the trend. Look at the line across weeks. A single reading tells you almost nothing.
What not to measure
Anything that swings more day to day than the change you are looking for.
A wearable estimate of sleep stages, which is an estimate and not a measurement.
Weight on one morning, which mostly records water.
A feeling you did not write down before starting, such as: quality of life.
When to stop
Stop if something new and unpleasant starts, and ask a pharmacist or doctor.
Stop if you cannot keep everything else steady, because the result will not mean anything.
Stop at the end of the window you set, and read the trend then.
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki does not work out an amount for anyone.
What is missing or unclear◇Read from sources, not yet reviewed
Claims that go past the evidence
Things said about this substance that sound reasonable, and the exact step that is missing between the evidence and the claim.
✗Goes past the evidence
That resveratrol is a direct SIRT1 activator or a calorie-restriction mimetic in humans
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That lifespan extension in yeast, worms and mice predicts anything about human healthspan
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That the French paradox is explained by dietary resveratrol — tested directly in Chianti and not supported
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That the null human trials are collateral damage from the misconduct case; they were run by independent groups and stand on their own
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Every line above can be traced to the study named beside it. Follow the link and read it.
The SIRT1 activation was an artefact of the assay substrate
In plain words
The enzyme resveratrol was famous for switching on turned out not to be switched on by it — the effect only appeared when the test used a fluorescent tag.
What was measured
That resveratrol is a direct SIRT1 activator and therefore a calorie-restriction mimetic
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Pacholec et al. tested resveratrol and the synthetic SIRT1 activators SRT1720, SRT2183 and SRT1460 against SIRT1 and found that apparent activation required a fluorophore-containing peptide substrate. With native peptide substrates the activation disappeared, and the compounds showed extensive off-target activity instead. This is a mechanistic correction rather than a misconduct finding, published by an independent pharmaceutical group, and it is the single most consequential paper in the resveratrol literature.
Written into the record, not signed off as a reviewed claim
A separate matter: 145 counts of data fabrication at the University of Connecticut
In plain words
A leading resveratrol researcher was found to have fabricated and falsified data 145 times, and eleven journals were formally notified.
What was measured
Not recorded
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
A three-year investigation by the University of Connecticut Health Center, prompted by an anonymous allegation in 2008 and covering more than seven years of laboratory activity, concluded that Dipak K. Das, professor of surgery and director of the Cardiovascular Research Center, was guilty of 145 counts of fabrication and falsification of data. The report ran to approximately 60,000 pages. Letters of notification were sent to 11 scientific journals; the Health Center froze externally funded research in the laboratory and declined US$890,000 in federal grants. Retraction notices followed, including in the Journal of Cellular and Molecular Medicine. This affected a specific body of cardioprotection work and did not produce the SIRT1 correction, which was independent, nor the null clinical trials, which were run by other groups.
Written into the record, not signed off as a reviewed claim
Poulsen 2013: high-dose resveratrol did nothing in obese men
In plain words
Four weeks of high-dose resveratrol in obese men changed nothing measurable, including the primary endpoint.
What was measured
Insulin sensitivity by hyperinsulinaemic euglycaemic clamp over four weeks
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
Randomised, placebo-controlled, double-blinded, parallel-group trial in 24 obese but otherwise healthy men, with insulin sensitivity by hyperinsulinaemic euglycaemic clamp as the primary outcome. Insulin sensitivity deteriorated insignificantly in both groups. Endogenous glucose production and glucose turnover and oxidation rates were unchanged. There was no effect on blood pressure, resting energy expenditure, lipid oxidation, ectopic or visceral fat content, or inflammatory and metabolic biomarkers. The authors wrote that the lack of effect disagrees with persuasive rodent data and raises doubt about the justification of resveratrol as a human nutritional supplement in metabolic disorders.
Written into the record, not signed off as a reviewed claim
Yoshino 2012: no metabolic improvement in nonobese women either
In plain words
A carefully controlled trial in healthy-weight postmenopausal women found no metabolic benefit, and measured the supposed molecular targets directly to show they had not moved either.
What was measured
Tissue-specific insulin sensitivity by clamp, and muscle and adipose expression of AMPK, SIRT1, NAMPT and PPARGC1A
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
Forty-five lean and overweight postmenopausal women were randomised to placebo, resveratrol 75 mg/day, or calorie restriction for 12 weeks. Plasma resveratrol rose, and nothing else did: no change in body composition, resting metabolic rate, plasma lipids or inflammatory markers, and no increase in liver, skeletal muscle or adipose tissue insulin sensitivity on a two-stage hyperinsulinaemic euglycaemic clamp with labelled tracers. The paper also measured the putative molecular targets directly — AMPK, SIRT1, NAMPT and PPARGC1A — in muscle and adipose tissue, and none was affected. Together with Poulsen 2013 this closes both ends of the metabolic hypothesis.
Written into the record, not signed off as a reviewed claim
Gliemann 2013: resveratrol blunted the benefits of exercise training
In plain words
Older men who took resveratrol while training got less out of the training than men who took placebo.
What was measured
Training-induced change in maximal oxygen uptake, mean arterial pressure and blood lipids over eight weeks
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
Twenty-seven healthy physically inactive men aged around 65 were randomised to 250 mg trans-resveratrol daily or placebo alongside eight weeks of high-intensity exercise training. Training raised maximal oxygen uptake 45% more in the placebo group than in the resveratrol group (P < 0.05), and mean arterial pressure fell in the placebo group only (-4.8 +/- 1.7 mmHg, P < 0.05). Resveratrol also abolished the exercise-induced improvements in LDL, the total-to-HDL cholesterol ratio and triglycerides (P < 0.05). Interstitial prostacyclin was lower and muscle thromboxane synthase higher in the resveratrol group. SIRT1 protein levels were unaffected. A supplement that reverses an established benefit is a stronger finding than one that produces none.
Written into the record, not signed off as a reviewed claim
Dietary resveratrol exposure predicted nothing over nine years
In plain words
Measuring how much resveratrol 783 older Italians were actually getting from their diet showed no link to inflammation, disease or death.
What was measured
That dietary resveratrol exposure explains the cardiovascular mortality pattern the French paradox described
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
The InCHIANTI prospective cohort followed 783 community-dwelling men and women aged 65 or older in two Chianti villages from 1998 to 2009, using 24-hour urinary resveratrol metabolites as the exposure. Over nine years 268 participants, 34.3%, died. Mortality across quartiles of urinary resveratrol was 34.4%, 31.6%, 33.5% and 37.4% (P = 0.67), with a hazard ratio of 0.80 (95% CI 0.54 to 1.17) for the lowest against the highest quartile. Resveratrol levels were not associated with CRP, IL-6, IL-1 beta, TNF, or prevalent or incident cardiovascular disease or cancer. This is the French-paradox hypothesis tested where it was born, with a direct biochemical exposure measure rather than a food questionnaire.
This order is fixed in code and does not count clicks or time on the page.
What is not here
3 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
The older medicine-wide conclusion held in this record
Written for a clinical reader, and about the medicine as a whole rather than about one indication, population and set of trials. RNAWiki does not treat it as a programme conclusion and no reviewer has signed it off in that form. It is here word for word because it is what the record holds.
A compound whose proposed target was shown not to be directly engaged, whose most enthusiastic laboratory produced 145 counts of data fabrication, and whose independent human trials — separately and on their own merits — repeatedly found nothing, including one that found resveratrol blunted the benefits of exercise.
Recorded evidence blocks (15)
Q1
What did Resveratrol's largest trial (2700 people) and its longest (12 years) measure?
2700 people in Resveratrol's largest registered study, 12 years in its longest registered window, measuring To determine if oral resveratrol administered for 12 months will blunt the aging associated increase in vascular stiffness as measured by Pulse Wave Velocity (PWV). ClinicalTrials.gov · 2026-09-01
57 na, 27 phase2, 18 phase1, 10 phase3, 4 early phase1, 3 phase4, 1 na or unstated; NCT02690064; 2027-01. Last human test completed 2026, NCT05377242.
Interpretation These counts include studies where Resveratrol was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
na
57
phase2
27
phase1
18
phase3
10
early phase1
4
phase4
3
2 more recorded rows
na or unstated
1
Last recorded human testNCT05377242
2026-06-22
recorded 2026-09-01 · last checked 2026-09-04
Q2
From yeast to human: where has Resveratrol shown lifespan?
C. elegans: lifespan, Drosophila: lifespan, yeast: lifespan, mouse: lifespan, rat: healthspan, dog: lifespan and human: mechanism-only (113): the rungs where Resveratrol has a recorded finding. Europe PMC and ClinicalTrials.gov · organism ladder · 2026-09-01
To determine if oral resveratrol administered for 12 months will blunt the aging associated increase in vascular stiffness as measured by Pulse Wave Velocity… — the recorded outcome words.
Show the evidence
C. elegans
lifespan
Drosophila
lifespan
yeast
lifespan
mouse
lifespan
rat
healthspan
dog
lifespan
1 more recorded row
humanNCT01842399
mechanism-only; To determine if oral resveratrol administered for 12 months will blunt the aging associated increase in vascular stiffness as measured by Pulse Wave Velocity (PWV).; 113
recorded 2026-09-01 · last checked 2026-09-04
Q3
The NIA ITP gave Resveratrol at 1200 ppm and 300 ppm from 12 and 4 months — did both sexes live longer?
905 mice; cohorts C2006, C2007; cohort rows are the workbook's own printed values; no median, percent change or survival statistic is derived from the per-animal data
Show the evidence
ITP cohort
C2006
resveratrol; 1200; 12.0 months; f, m; ITP_C2006_Lifespan.xlsx
C2006
resveratrol; 300; 12.0 months; f, m; ITP_C2006_Lifespan.xlsx
C2007
resveratrol; 300; 4.0 months; f, m; ITP_C2007_Lifespan.xlsx
recorded 2026-09-04 · last checked 2026-09-04
Q4
9 of Resveratrol's trials stopped: accrual/recruitment, funding/business, other?
accrual/recruitment (2), funding/business (2) and other (5): Resveratrol's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"no participant enrollment"; 9 of 113 registered studies
Show the evidence
Trial
NCT00654667
withdrawn; "no participant enrollment"
NCT01158417
terminated; "FDA clinical hold requiring IND submission, product not available in the market anymore"
NCT01842399
terminated; "The protocol experienced slow accrual."
NCT02261844
withdrawn; "No funding"
NCT02549924
terminated; "no financial support"
NCT03866200
terminated; "Inability to recruit target number"
3 further recorded trials
NCT04266353
withdrawn; "Due to COVID-19"
NCT04400890
terminated; "Feasibility"
NCT04542993
terminated; "Difficulty accruing patients"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Mouse studies of Resveratrol used 300 (lo) and 1200 (hi) ppm — over how long?
Mouse studies of Resveratrol used "300 (lo) and 1200 (hi) ppm". clinicaltrials.gov+jax-mpd-itp · 2026-09-04
17 recorded entries; mouse, human; oral; also "300 ppm", "Resveratrol 40 mg oral three times a day", "Resveratrol 40mg"
Show the evidence
mouse
resveratrol C2006
300 (lo) and 1200 (hi) ppm
resveratrol C2006
300 (lo) and 1200 (hi) ppm
resveratrol C2007
300 ppm
human
NCT01158417
oral; Resveratrol 40 mg oral three times a day
NCT01158417
Resveratrol 40mg
NCT01158417
oral; Resveratrol 500 mg oral once daily.
NCT01158417
Resveratrol 500 mg
NCT01324089
Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
NCT01324089
Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
8 more recorded rows
humanNCT01638780
resVida (99% pure trans-resveratrol) provided by DSM Nutritional Products, Ltd.
humanNCT01997762
All Natural Resveratrol 98% Super Strength
humanNCT02129595
resVida (99% pure trans-resveratrol)
humanNCT02565979
resVida (99% trans-resveratrol)
humanNCT03091868
BIA 6-512 25 mg
humanNCT03091868
BIA 6-512 100 mg
humanNCT03095092
BIA 6-512 400 mg
humanNCT03095105
200 mg BIA 6-512
recorded 2026-09-04 · last checked 2026-09-04
Q6
More Resveratrol was worse in human: at what point?
Hormetic in human: "In accordance with hormesis, polyphenols display biphasic dose-response effects by activating at a low dose the Nrf2 pathway resulting in the upregulation of antioxidant <i>vitagenes</i>, as in the case of heme oxygenase-1 upregulated by hidrox<sup>®</sup> or curcumin and sirtuin-1 activated by resveratrol to inhibit…" Europe PMC · dose-response search · 2026-08-11
5 recorded sentences naming Resveratrol; hormesis, dose-response
Show the evidence
hormesisPMID 38671931
"In accordance with hormesis, polyphenols display biphasic dose-response effects by activating at a low dose the Nrf2 pathway resulting in the upregulation of antioxidant <i>vitagenes</i>, as in the case of heme oxygenase-1 upregulated by hidrox<sup>®</sup> or curcumin and sirtuin-1 activated by resveratrol to inhibit reactive oxygen species (ROS) overproduction, microbiota dysfunction and…"
dose-response
PMID 42588976
"A dose-response trial was conducted with 0, 10, 60, 110, and 160 mg·kg<sup>-1</sup> of resveratrol."
PMID 42650499
"Future studies should combine standardized dose-response feeding trials with gas chromatography-mass spectrometry (GC-MS)-based volatile profiling, lipid and protein oxidation indices, instrumental texture analysis, sensory evaluation, and shelf-life testing before resveratrol can be recommended as a robust feed-based strategy for improving edible fish muscle quality."
PMID 42101279
"Resveratrol is widely studied for its anti-inflammatory properties, yet the dose-response relationship between its molecular effects and potential organ toxicity in healthy animals remains poorly characterized."
PMID 40580309
"Therefore, this systematic review and dose-response meta-analysis was performed to evaluate the effect of resveratrol on renal function."
recorded 2026-08-11 · last checked 2026-09-04
Q7
Resveratrol's half-life is 9.2 ± 0.6 hours — which schedules were studied?
9.2 ± 0.6 hours, the half-life Resveratrol's label states. openfda-label · 2026-08-28
Show the evidence
half life
9.2 ± 0.6 hours hours; The absorption of a dietary relevant 25-mg oral dose was at least 70%, with peak plasma levels of resveratrol and metabolites of 491 +/- 90 ng/ml (about 2 microM) and a plasma half-life of 9.2 +/- 0.6 h.
recorded 2026-08-28 · last checked 2026-09-04
Q8
Could one person measure Resveratrol's effect on auditory verbal learning task?
Auditory verbal learning task: measured in Resveratrol's trials.
Interpretation auditory verbal learning task is the recorded endpoint.
0; NCT00654667; PHASE2; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; WITHDRAWN
Q9
Which of acute change in exercise capacity, acute change in flow mediated dilation and adverse events did Resveratrol's trials measure?
acute change in exercise capacity, acute change in flow mediated dilation and adverse events lead 40 outcome terms across Resveratrol's trials. ClinicalTrials.gov · 2026-09-01
Interpretation nf kb, vascular function, c reactive protein, adverse events, glucose control and aerobic capacity follow.
Show the evidence
auditory verbal learning task
1
brachial artery flow mediated dilation
1
metabolic parameters
1
nf kb
1
vascular function
1
c reactive protein
1
14 more recorded rows
adverse events
1
glucose control
1
aerobic capacity
1
liver fat content
1
insulin sensitivity
1
quality of life
1
cardiac function
1
beta cell function
1
alaninaminotransferase
1
triglycerides levels at week 12
1
high density lipoprotein levels at week 12
1
systolic blood pressure at week 12
1
waist circumference at week 12
1
diastolic blood pressure at week 12
1
recorded 2026-09-01 · last checked 2026-09-04
Q10
Which of Resveratrol's 3 ongoing trials reports first?
Acute Change in Flow mediated dilation; Change in endothelial function; latest 2027-07-01
Show the evidence
Trial
NCT02690064
"Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF"; n 13; "Acute Change in Flow mediated dilation"; 2027-01
NCT03762096
"Short Interval Resveratrol Trial in Cardiovascular Surgery"; n 40; "Change in endothelial function"; 2026-12-31
NCT04449198
"Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1"; n 24; "Change in AUC for ET-1 + BQ-123"; 2027-07-01
recorded 2026-09-01 · last checked 2026-09-04
Q11
Which 68 trials of Resveratrol posted no result?
Posted no result
68 of 68 completed trials
Registrations
NCT03091868, NCT03095092, NCT03093389, NCT03095105, NCT03094156 and NCT03097211, and 62 more
Completion dates
oldest 2005-02-28; newest 2024-07-30
Show the evidence
Trial
NCT03091868
2005-02-28
NCT03095092
2005-07-07
NCT03093389
2005-07-29
NCT03095105
2006-03-02
NCT03094156
2006-07-11
NCT03097211
2006-10-20
14 further recorded trials
NCT00433576
2009-03
NCT00256334
2009-04
NCT00721877
2009-07
NCT00823381
2010-12
NCT01038089
2010-12
NCT00998504
2011-01
NCT01173640
2011-02
NCT01768507
2011-03
NCT01615445
2011-08
NCT01150955
2011-11
NCT01324089
2012-03
NCT01492114
2012-03
NCT01370889
2012-07
NCT02247596
2012-10
Q12
At the median, Resveratrol's trials enrolled 37 people — anything larger?
Median enrolment
37
Largest enrolment
2700
Registered trials counted
113
Q13
What do 12 spontaneous reports say about Resveratrol — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Resveratrol appears in spontaneous reports to regulators. Across the 2 most-reported reaction terms, 12 reaction mentions were counted: hepatitis 6; hyperbilirubinaemia 6. open-targets-adr · CHEMBL165 · 2026-06-24
Show the evidence
hepatitis
6
hyperbilirubinaemia
6
recorded 2026-06-24 · last checked 2026-09-04
Q14
Was Resveratrol studied with fasting and exercise?
fasting and exercise are named in Resveratrol's label sentences: "We observed a statistically significant reduction in the C-reactive protein (CRP) (P = 0.041), Fasting blood sugar (FBS) (P = 0.002), Alkaline phosphatase (ALP) (P = 0.034), IL-1β (P = 0.011), TNF-α (P = 0.001), and White blood cell (WBC) (P = 0.043), Platelet count (PLT) (P = 0.042), Neutrophils…" openfda-label+europepmc · 2025-04-30
2 recorded statements; fasting, exercise
Show the evidence
fasting
We observed a statistically significant reduction in the C-reactive protein (CRP) (P = 0.041), Fasting blood sugar (FBS) (P = 0.002), Alkaline phosphatase (ALP) (P = 0.034), IL-1β (P = 0.011), TNF-α (P = 0.001), and White blood cell (WBC) (P = 0.043), Platelet count (PLT) (P = 0.042), Neutrophils (NUT) (P = 0.015) and an increase in Lymphocyte (LYM) (P = 0.010) in the resveratrol treated group…
exercise
Forty-one older adults [mean (±SD) age of 72.1 (6.8) years] participated in a 12-week supervised center-based, multi-component exercise training intervention [2×/week; 80 min/session] and were randomized to one of two resveratrol dosages [Low: 500 vs. High:1000 mg/day] or a cellulose-based placebo.
recorded 2025-04-30 · last checked 2026-09-04
Q15
What is recorded about Resveratrol and senolytic?
"Comparative consideration is also given to established aging-relevant candidates, including metformin, rapamycin, resveratrol, GLP-1 receptor agonists, NAD<sup>+</sup> modulators, and senolytic strategies, in order to contextualize the potential relevance and limitations of metabolic-vascular pathway modulation in aging research." — where Resveratrol and senolytic appear together. Europe PMC · pathway abstract search · 2026-08-28
"Comparative consideration is also given to established aging-relevant candidates, including metformin, rapamycin, resveratrol, GLP-1 receptor agonists, NAD<sup>+</sup> modulators, and senolytic strategies, in order to contextualize the potential relevance and limitations of metabolic-vascular pathway modulation in aging research."
NAD+PMID 42534639
"Comparative consideration is also given to established aging-relevant candidates, including metformin, rapamycin, resveratrol, GLP-1 receptor agonists, NAD<sup>+</sup> modulators, and senolytic strategies, in order to contextualize the potential relevance and limitations of metabolic-vascular pathway modulation in aging research."
sirtuin
PMID 42289992
"It examines the preclinical efficacy of SIRT1 activators, such as resveratrol and SRT1720, and discusses challenges including dose dependency, specificity, and barriers to clinical translation."
PMID 42570712
"Therapeutic targets of these various nodes include UA, PGC-1α activator ZLN005, and SIRT1 activators, such as resveratrol or nicotinamide riboside."
"Trans-resveratrol (3,5,4′-trihydroxystilbene) is a natural polyphenolic antioxidant widely used in anti-aging dermocosmetics for its strong radical-scavenging capacity and its activation of cell-protective pathways such as SIRT1."
AMPK
PMID 42400730
"Resveratrol shows neuroprotective effects in preclinical studies across a number of neurodegenerative illnesses, including Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Huntington's disease (HD), and it enhances mitochondrial function through stimulation of the AMPK/SIRT1/PGC-1α pathway, thereby improving mitochondrial oxidative capacity and ATP…"
PMID 42400730
"Resveratrol activates SIRT1 and AMPK signaling in preclinical models, enhancing mitochondrial biogenesis, lowering apoptosis, and restoring cellular resilience."
mTORPMID 42607934
"Experimental and clinical evidence indicates that phytochemicals engage conserved ageing hubs spanning insulin-IGF signaling, AMPK-mTOR nutrient sensing, redox regulation, and mitochondrial quality control - exemplified by berberine via AMPK, curcumin via NF-κB, and resveratrol via SIRT1."
AMPKPMID 42607934
"Experimental and clinical evidence indicates that phytochemicals engage conserved ageing hubs spanning insulin-IGF signaling, AMPK-mTOR nutrient sensing, redox regulation, and mitochondrial quality control - exemplified by berberine via AMPK, curcumin via NF-κB, and resveratrol via SIRT1."
autophagy
PMID 41925931
"Pharmacologic modulators such as rapamycin, resveratrol, metformin, and propofol have shown potential in restoring autophagic balance and reducing infarct size in preclinical models."
PMID 42412302
"Resveratrol (RV), a natural polyphenolic compound, exhibits anti-aging properties through the regulation of autophagy and oxidative stress; however, its mechanisms in AD remain incompletely understood."
NAD+PMID 41714893
"Interventions targeting this axis-NAD⁺ precursors (NMN/NR), Sirtuin activators (resveratrol/quercetin), and lifestyle strategies (intermittent fasting/exercise)-demonstrate efficacy in preclinical models: NMN restores sperm quality (+40% normality) and testosterone synthesis; resveratrol reduces sperm DNA fragmentation by 45% via SIRT3 activation."
mTORPMID 42475944
"Resveratrol targeted the AMPK/mTOR signaling axis, showing consistent suppression of cancer stem-like cells and tumor growth inhibition in xenografted models."
autophagyPMID 38551444
"To explore whether resveratrol can postpone the fibrosis associated with diabetic cardiomyopathy (DCM) by modulating the mitochondrial autophagy response through the AMPK/SIRT1-mediated IRE1α/PINK signaling pathway."
mTORPMID 42293333
"Resveratrol alleviates DPN by modulating oxidative stress, apoptosis, and neuroinflammation via the AMPK/mTOR/Bcl-2 axis and macrophage polarization."
NAD+PMID 41011644
"Sirtuin 1 (SIRT1), a NAD<sup>+</sup>-dependent deacetylase, regulates endothelial and vascular smooth muscle function, and its activation by compounds such as resveratrol or SRT1720 shows therapeutic potential by reducing pulmonary and right ventricular pressures and limiting vascular remodeling in both preventive and therapeutic experimental models, highlighting their potential translational…"
recorded 2026-08-28 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · NIA ITP via the JAX Mouse Phenome Database · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 12 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.